AQP4 expression in striatal primary cultures is regulated by dopamine--implications for proliferation of astrocytes.
Proliferation of astrocytes plays an essential role during ontogeny and in the adult brain, where it occurs following trauma and in inflammation and neurodegenerative diseases as well as in normal, healthy mammals. The cellular mechanisms underlying glial proliferation remain poorly understood. As dopamine is known to modulate proliferation in different cell populations, we investigated the effects of dopamine on the proliferation of striatal astrocytes in vitro. We found that dopamine reduced proliferation. As proliferation involves, among other things, a change in cell volume, which normally comes with water movement across the membrane, water channels might represent a molecular target of the dopamine effect. Therefore we studied the effect of dopamine on aquaporin 4 (AQP4) expression, the main aquaporin subtype expressed in glial cells, and observed a down-regulation of the AQP4-M23 isoform. This down-regulation was the cause of the dopamine-induced decrease in proliferation as knockdown of AQP4 using siRNA techniques mimicked the effects of dopamine on proliferation. Furthermore, stimulation of glial proliferation by basic fibroblast growth factor was also abolished by knocking down AQP4. In addition, blocking of AQP4 with 10 mum tetraethylammonium inhibited osmotically induced cell swelling and stimulation of glial cell proliferation by basic fibroblast growth factor. These results demonstrate a clear-cut involvement of AQP4 in the regulation of proliferation and implicate that modulation of AQP4 could be used therapeutically in the treatment of neurodegenerative diseases as well as in the regulation of reactive astrogliosis by preventing or reducing the glia scar formation, thus improving regeneration following ischemia or other trauma.
Küppers
Eva
E
Institute of Anatomy, Eberhard-Karls University of Tübingen, Tübingen, Germany. eva.kueppers@uni-tuebingen.de
Gleiser
Corinna
C
Brito
Veronica
V
Wachter
Britta
B
Pauly
Thorsten
T
Hirt
Bernhard
B
Grissmer
Stephan
S
D000818:Animals; D000831:Animals, Newborn; D051401:Aquaporin 4 / Q000235:genetics*; D001253:Astrocytes / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D049109:Cell Proliferation / Q000187:drug effects*; D002478:Cells, Cultured; D003342:Corpus Striatum / Q000166:cytology / Q000254:growth & development / Q000378:metabolism*; D004298:Dopamine / Q000378:metabolism* / Q000494:pharmacology; D015536:Down-Regulation / Q000187:drug effects / Q000235:genetics; D016222:Fibroblast Growth Factor 2 / Q000494:pharmacology; D005911:Gliosis / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism*; D051379:Mice; D008807:Mice, Inbred BALB C; D026902:Potassium Channel Blockers / Q000494:pharmacology; D034622:RNA Interference; D012333:RNA, Messenger / Q000187:drug effects / Q000378:metabolism; D019789:Tetraethylammonium / Q000494:pharmacology; D014882:Water-Electrolyte Balance / Q000187:drug effects / Q000502:physiology
C496031:Aqp4 protein, mouse; D051401:Aquaporin 4; D026902:Potassium Channel Blockers; D012333:RNA, Messenger; D016222:Fibroblast Growth Factor 2; D019789:Tetraethylammonium; D004298:Dopamine